Disclosure Of Cash Flow Statement [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166253

Concept 2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
As at
2020-12-31
Disclosure of cash flow statement [text block]
Description of accounting policy for determining components of cash and cash equivalents [text block]
2
Cash and cash equivalents if different from statement of financial position [abstract]
Cash and cash equivalents
43,457 EUR
50,012 EUR
64,399 EUR
Income taxes paid (refund) [abstract]
Income taxes paid (refund), classified as operating activities
349,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.